Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer

Table 2 Clinical characteristics of samples and classifier performance

	TX-TOTHILL	TX-YOSHIHARA
	Training set	Test set
number of patients	145	71
no relapse > 22 months (sensitive)	63	42
relapse < 12 months (resistant)	82	29
average PFS	21.69 +/− 21.47	25.86 +/− 21.68
PFS, sensitive group	39.33 +/− 22.40	40.21 +/− 16.72
PFS, resistant group	8.13 +/− 2.77	5.07 +/− 3.09
FIGO stage
early stage (I-IIA)	15	0
advanced stage (IIB-IV)	130	71
Chemotherapy
platinum-based drug	29	0
platinum-based drug and taxanes	116	71
array platform	Affymetrix Human Genome U133 Plus 2.0	Agilent Whole Human Genome Microarray 4x44K
optimism corrected AUC	0.786	0.721

Clinical characteristics of the patient samples used in transcriptomics profiling and performance of the prognostic transcript panel classifier in identifying sensitive and resistant specimens

ISSN: 1752-0509